Senti Biosciences Holdings, Inc. (SNTI) is a Nasdaq-listed, clinical-stage biotechnology company developing SENTI-202, a CAR-NK (chimeric antigen receptor natural killer) cell therapy for relapsed/refractory blood cancers including acute myeloid leukemia (AML). The shares trade as a low-priced stock, and the question of whether they can reach a double-digit price target turns as much on a complex corporate restructuring as on the science.
Three current, attributable analyst price targets were reviewed for this analysis. H.C. Wainwright carries a Buy rating with a $12 target, Chardan Capital analyst Geulah Livshits rates the stock Buy and raised the target from $11 to $12 in May 2026, and Leerink Partners initiated coverage with a Buy rating and a $6 target. The arithmetic mean of these three figures is $10.00, rounded to $10, with an approximate range of $6 to $12.
Aggregators display slightly different consensus figures—roughly $9 to $13.50—because they use different inclusion windows and retain older targets. The $10 figure used here is a calculated mean, not an official published consensus. All three analysts rate the stock positively, but the wide gap between the $6 low and the $12 high reflects genuine disagreement about how much the company's balance sheet and restructuring, rather than its science, will shape shareholder value. Chardan's target changes—a cut from $13 to $11 in March 2026 followed by a raise back to $12 in May—illustrate how quickly the outlook shifts for a pre-revenue biotech.
The stock last traded near $0.16, with a market capitalization of roughly $14 million in mid-2026. Reaching $10 would require an increase of approximately 6,000%, a very large move by any standard. A meaningful portion of any apparent path is structural rather than fundamental: the company has authorized a reverse stock split in a range of 1-for-20 to 1-for-50, at the board's discretion, to maintain Nasdaq's $1.00 minimum bid price. A reverse split would mechanically raise the per-share price without changing the company's total market value, so investors should interpret the $10 target in per-share terms with caution.
The fundamental path depends on SENTI-202's clinical progress, the completion of a July 2026 merger agreement that divests the Midco operating business, and the company's ability to secure ongoing funding without excessive dilution.
Reliable, durable technical levels are limited for such a low-priced stock, but two structural reference points matter. The $1.00 Nasdaq minimum bid requirement is the key threshold the company is trying to reclaim, and the roughly $0.342 conversion price on the senior secured convertible notes indicates where substantial new shares could be issued. The stock's status as a sub-$1 issue makes it prone to wide percentage swings on modest dollar moves.
Analyst price targets generally reflect a research horizon of about 12 months, though the firms do not publish identical timelines. Investors should monitor SENTI-202 clinical data updates, completion of the merger and Midco divestiture, any board decision on the reverse stock split ratio, cash runway and financing announcements, Nasdaq compliance status, and analyst rating or target revisions.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. For a volatile, low-priced name like SNTI, such tools can help traders discover opportunities, monitor positions, and spot changing trends more efficiently than manual screening. Explore the signals to complement your own research.
The central target of $10 is the calculated mean of three analyst price targets spanning $6 to $12, not a guarantee or an official consensus. From a price near $0.16, reaching it would require an enormous move, and part of that apparent gap could be closed mechanically by a reverse stock split rather than by fundamental progress. The SENTI-202 oncology data and unanimous Buy ratings are the clearest supports, while the restructuring, dilution, Nasdaq compliance issues, and clinical uncertainty are the principal obstacles. Investors should focus next on trial data, the reverse split decision, and the company's financing position rather than treating the target as a prediction.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, SNTI has been loosely correlated with PPBT. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if SNTI jumps, then PPBT could also see price increases.
| Ticker / NAME | Correlation To SNTI | 1D Price Change % | ||
|---|---|---|---|---|
| SNTI | 100% | +11.81% | ||
| PPBT - SNTI | 58% Loosely correlated | +11.94% | ||
| INBX - SNTI | 41% Loosely correlated | -0.02% | ||
| RXRX - SNTI | 35% Loosely correlated | +1.13% | ||
| DSGN - SNTI | 34% Loosely correlated | +1.13% | ||
| DYN - SNTI | 33% Poorly correlated | +0.39% | ||
More | ||||